Short Interest in SciSparc Ltd. (NASDAQ:SPRC) Expands By 5,157.1%

SciSparc Ltd. (NASDAQ:SPRC) was the target of a large growth in short interest during the month of May. As of May 29th, there was short interest totaling 378,196 shares, a growth of 5,157.1% from the May 14th total of 7,194 shares. Based on an average daily volume of 3,858,258 shares, the short-interest ratio is currently 0.1 days. Currently, 67.9% of the shares of the stock are short sold.

SciSparc Stock Performance

Shares of NASDAQ SPRC opened at $9.31 on Wednesday. The firm’s 50-day moving average price is $5.93 and its 200-day moving average price is $8.55. SciSparc has a 12-month low of $2.98 and a 12-month high of $80.10.

SciSparc (NASDAQ:SPRC) last announced its earnings results on Wednesday, April 29th. The company reported ($31.60) earnings per share (EPS) for the quarter. The firm had revenue of $0.20 million for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of SciSparc in a report on Tuesday, May 26th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, SciSparc has a consensus rating of “Sell”.

About SciSparc

SciSparc AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.

The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function.